Sign in
TerminatedPhase 1

C-TIL051 in Non-Small Cell Lung Cancer

Key facts

Who runs it
AbelZeta Inc.
Where
New Orleans, Pittsburgh, and Raleigh, United StatesSee the 3 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
1 person enrolled
Started
29 Feb 2024
Ended
30 Dec 2025
Type of study
Interventional
Treatments tested
  • C-TIL051
Record updated
5 January 2026
Why it stopped
Sponsor decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Able to understand and give written informed consent
  • Histologically and cytologically confirmed diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma or squamous histology
  • Planned for treatment with an anti-PD1 agent
  • Tumor accessible by surgery, previously not irradiated and ≥ 1.5 cm in diameter
  • Measurable disease after resection of tumor by RECIST 1.1
  • ECOG ≤ 1
  • Expected survival > 6 months
  • Adequate organ and marrow function
  • ECHO, MUGA or cardiac stress test within past 6 months showing LVEF >50% and without evidence of reversible ischemia
  • Pulmonary function tests within past 6 months showing DLCO >50% of predicted

Who cannot take part

  • Previous treatment with PD1/PDL1 inhibitor for metastatic disease, Immune checkpoint blockade (ICB) given as part of definitive therapy for stage Ib-III disease with surgery or after chemo/radiation is acceptable if last dose of ICB is at least 6 months prior to enrollment in this study
  • Current or prior use of any immunosuppressive medications within 14 days before tumor harvest
  • Live vaccine within 30 days of tumor harvest
  • Unresolved greater than grade 1 toxicity (CTCAE v5.0) from previous therapy
  • History of leptomeningeal metastases
  • Uncontrolled intercurrent illness
  • Known history of HIV+ or AIDS, hepatitis C, acute or chronic active hepatitis B or other serious chronic infection
  • History of allogeneic organ transplant
  • History of primary immunodeficiency
  • Hypersensitivity to anti-PD1 agent, cyclophosphamide, fludarabine, interleukin-2, gentamicin, or any excipient
  • Any condition that may interfere with evaluation of study treatment, safety or study results
  • Active infection that requires IV antibiotics within 7 days of tumor harvest
  • History of interstitial pneumonitis of autoimmune etiology that is symptomatic or requires treatment
  • Pulmonary disease history requiring escalating amounts of oxygen > 2L
  • Known autoimmune conditions requiring systemic immune suppression therapy other than low dose prednisone or equivalent
  • Other malignancy, other than cutaneous localized) that required active treatment in the last 2 years
  • Known driver mutations such as EGFR, ALK, ROS1, RET, METex14, and NTRK alterations
  • Known active CNS metastases which are symptomatic
  • Women who are pregnant or lactating
  • Women of childbearing potential or fertile men who are unwilling to use effective contraception during study and 6 months after treatment

Where in United States

  • Ochsner/MD Anderson Cancer CenterNew Orleans, United States
  • Allegheny Health Network - West Penn HospitalPittsburgh, United States
  • Duke Center for Cancer ImmunotherapyRaleigh, United States

About the trial

What the trial wants to find out

The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer.

Read full original descriptionShow less

The purpose of this study is to:

1. Test the safety and ability for subjects to tolerate the TIL therapy 2. Measure to see how the NSCLC responds to the TIL therapy

Participants will be asked to:

* Provide a tumor sample prior to the start of any treatment which will be used to make the C-TIL051. * Receive standard of care treatment until their lung cancer no longer responds * When necessary, the C-TIL051 will be manufactured by the sponsor and sent back to the site * Subject will then receive chemotherapy (called lymphodepletion) for 3 days followed by 2 days of rest * C-TIL051 will then be infused on day 0 followed by NKTR-255 (IL-15) about 12 to 24 hours later * Pembrolizumab will be administered every 3 weeks for up to 2 years

NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist molecule designed to increase the proliferation and survival of memory CD8+ T cells and enhance the formation of long-term immunological memory which may lead to sustained anti-cancer immune response. The combination of NKTR 255 and TIL's could improve proliferation and persistence of cellular therapies leading to enhanced anti-tumor activity.

The group in the trial

  • C-TIL051Treatment being tested

    C-TIL051 plus IL-15 (NKTR-255) and Pembrolizumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer
Record updated
5 January 2026